Quantcast
Home > Quotes > APLS
APLS

Apellis Pharmaceuticals, Inc. Common Stock (APLS) Quote & Summary Data

$18
*  
0.06
0.33%
Get APLS Alerts
*Delayed - data as of Dec. 12, 2018 9:37 ET  -  Find a broker to begin trading APLS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    APLS Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 17.85 / $ 18.76
1 Year Target
40
Today's High / Low
$ 18.34 / $ 17.6819
Share Volume
2,080
50 Day Avg. Daily Volume
294,310
Previous Close
$ 17.94
52 Week High / Low
$ 32 / $ 11.45
Market Cap
1,011,206,232
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.29
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.7

Intraday Chart

Shares Traded

Share Volume:
2,080
50 Day Avg. Daily Volume:
294,310

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.29

Trading Range

The current last sale of $18 is 57.21% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 18.34 $ 32
 Low: $ 17.6819 $ 11.45

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control a broad array of complement-dependent autoimmune and inflammatory diseases. We have the most advanced clinical program targeting C3. We believe that our lead product candidate, APL-2, has the potential to be a best-in-class treatment that may address the limitations of existing treatment options or provide a treatment option where there currently is none.  ... More ...  


Risk Grade

Where does APLS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 18.31
Open Date:
Dec. 12, 2018
Close Price:
$ 17.94
Close Date:
Dec. 11, 2018

Consensus Recommendation

Analyst Info